Development of a metabolites risk score for one-year mortality risk prediction in pancreatic adenocarcinoma patients

PURPOSE: Survival among patients with adenocarcinoma pancreatic cancer (PDCA) is highly variable, which ranges from 0% to 20% at 5 years. Such a wide range is due to tumor size and stage, as well other patients' characteristics. We analyzed alterations in the metabolomic profile, of PDCA patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Fontana, Andrea, Copetti, Massimiliano, Di Gangi, Iole Maria, Mazza, Tommaso, Tavano, Francesca, Gioffreda, Domenica, Mattivi, Fulvio, Andriulli, Angelo, Vrhovsek, Urska, Pazienza, Valerio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2016
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891018/
https://www.ncbi.nlm.nih.gov/pubmed/26840268
http://dx.doi.org/10.18632/oncotarget.7108

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4891018/
https://www.ncbi.nlm.nih.gov/pubmed/26840268
http://dx.doi.org/10.18632/oncotarget.7108

Ejemplares similares